Gizem Pire
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gizem Pire has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Ali Şahin
SİVAS CUMHURİYET ÜNİVERSİTESİ, TIP FAKÜLTESİ
1 shared publication Ali Şahi̇n
1 shared publicationBeliz Karataş
Binali Yıldırım University Mengücek Gazi Training and Research Hospital Erzincan Türkiye
1 shared publication- Beliz Karataş
Sivas Cumhuriyet Üniversitesi
1 shared publication Burak Karakaş
1 shared publicationBurcu Nur Özdamar
Clinic of Internal Medicine Gebze Fatih State Hospital Kocaeli Türkiye
1 shared publication
Latest Publications
- Open Access
- 8 January 2026
- Published by Bezmialem Vakif University in Bezmialem Science
The Effects of Medications Used in the Treatment of Rheumatological Diseases on Pregnancy and Fertilization: A Single-center Experience
The Effects of Medications Used in the Treatment of Rheumatological Diseases on Pregnancy and Fertilization: A Single-center Experience - Bezmialem Science
- 8 January 2026
- Published by Bezmialem Vakif University in Bezmialem Science
Open AccessThe Effects of Medications Used in the Treatment of Rheumatological Diseases on Pregnancy and Fertilization: A Single-center Experience
The Effects of Medications Used in the Treatment of Rheumatological Diseases on Pregnancy and Fertilization: A Single-center Experience - Bezmialem Science
- 1 December 2024
- Published by Bentham Science Publishers Ltd. in Endocrine, Metabolic & Immune Disorders - Drug Targets
- Vol. 24 (15) , 1842-1855
Effects of Metformin Therapy on Thyroid Volume and Functions in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Single-center Prospective Study
Objective: Patients with impaired glucose metabolism have increased thyroid volume and a higher prevalence of nodules. Yet, some studies show that there is an improvement in these thyroid parameters after diabetes treatment. Our observational study aimed to reveal the effect of treatment on thyroid function, thyroid volume, and the presence of nodules in newly diagnosed type 2 diabetes mellitus (T2DM) patients who were started on metformin treatment. Methods: Euthyroid and subclinically hypothyroid patients with a serum TSH level of <10 mU/L, who were newly diagnosed with T2DM and started on metformin as an antidiabetic treatment and not used any thyroid medication previously, were included in our study. Patients' characteristics were recorded. Baseline and 6th-month serum thyroid function tests were scheduled. Baseline and 6th-month thyroid gland characteristics were examined by thyroid ultrasonography. Results: A total of 101 (37 males, 64 females) newly diagnosed T2DM patients with euthyroid (n=95) or subclinical hypothyroidism (n=6) were included in the study. The mean age of the patients was 53.02 ± 11.9 years, and the mean BMI was 29.60 ± 3.9 kg/m2. Fifty-two (52%) patients were classified as obese. Body weight, BMI, serum TSH, ALT, Anti-TPO levels, and thyroid volume decreased significantly in the 6th-month compared to baseline values (p = 0.000; p = 0.000; p = 0.011; p = 0.022; p = 0.000, respectively). Serum anti-Tg, fT4, fT3 levels, and thyroid nodule count did not change significantly. A high agreement was found between the baseline and 6thmonth nodule counts (gamma= 0.886; p <0.001) and the presence of multi-nodularity in the thyroid (gamma= 0.941; p <0.001), but no significant change was observed. Anti-TPO levels showed a significant decrease in both with and without obesity groups at the end of 6 months (p = 0.003, p = 0.009, respectively). Serum TSH level decreased significantly only in non-obese subjects (p = 0.004), and thyroid volume decreased significantly only in obese subjects (p = 0.000). Conclusion: Our results suggest that metformin treatment significantly reduces body weight, BMI, thyroid volume, and serum TSH, ALT, and Anti-TPO levels in patients with newly diagnosed T2DM. Moreover, serum TSH levels showed a significant decrease in non-obese subjects, while thyroid volume showed a significant decrease in obese subjects.
- 1 December 2024
- Published by Bentham Science Publishers Ltd. in Endocrine, Metabolic & Immune Disorders - Drug Targets
- Vol. 24 (15) , 1842-1855
Effects of Metformin Therapy on Thyroid Volume and Functions in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Single-center Prospective Study
Objective: Patients with impaired glucose metabolism have increased thyroid volume and a higher prevalence of nodules. Yet, some studies show that there is an improvement in these thyroid parameters after diabetes treatment. Our observational study aimed to reveal the effect of treatment on thyroid function, thyroid volume, and the presence of nodules in newly diagnosed type 2 diabetes mellitus (T2DM) patients who were started on metformin treatment. Methods: Euthyroid and subclinically hypothyroid patients with a serum TSH level of <10 mU/L, who were newly diagnosed with T2DM and started on metformin as an antidiabetic treatment and not used any thyroid medication previously, were included in our study. Patients' characteristics were recorded. Baseline and 6th-month serum thyroid function tests were scheduled. Baseline and 6th-month thyroid gland characteristics were examined by thyroid ultrasonography. Results: A total of 101 (37 males, 64 females) newly diagnosed T2DM patients with euthyroid (n=95) or subclinical hypothyroidism (n=6) were included in the study. The mean age of the patients was 53.02 ± 11.9 years, and the mean BMI was 29.60 ± 3.9 kg/m2. Fifty-two (52%) patients were classified as obese. Body weight, BMI, serum TSH, ALT, Anti-TPO levels, and thyroid volume decreased significantly in the 6th-month compared to baseline values (p = 0.000; p = 0.000; p = 0.011; p = 0.022; p = 0.000, respectively). Serum anti-Tg, fT4, fT3 levels, and thyroid nodule count did not change significantly. A high agreement was found between the baseline and 6thmonth nodule counts (gamma= 0.886; p <0.001) and the presence of multi-nodularity in the thyroid (gamma= 0.941; p <0.001), but no significant change was observed. Anti-TPO levels showed a significant decrease in both with and without obesity groups at the end of 6 months (p = 0.003, p = 0.009, respectively). Serum TSH level decreased significantly only in non-obese subjects (p = 0.004), and thyroid volume decreased significantly only in obese subjects (p = 0.000). Conclusion: Our results suggest that metformin treatment significantly reduces body weight, BMI, thyroid volume, and serum TSH, ALT, and Anti-TPO levels in patients with newly diagnosed T2DM. Moreover, serum TSH levels showed a significant decrease in non-obese subjects, while thyroid volume showed a significant decrease in obese subjects.
- Open Access
- 4 June 2023
- Published by Ahi Evran Medical Journal, Kirsehir Ahi Evran University in Ahi Evran Medical Journal
- Vol. 8 (1) , 126-129
Secondary Anti-phospholipid Antibody Syndrome Due to Systemic Lupus Erythematosus: A Case Report with Superior Mesenteric Artery Involvement
Antiphospholipid antibody syndrome (APS); is a disease characterized by anti-phospholipid protein antibody positivity as well as recurrent vascular thrombosis and/or pregnancy loss. When no underlying disease is detected, it is classified as primary type; when there is another underlying rheumatologic disease, it is classified as secondary type. Secondary APS, most commonly develops due to systemic lupus erythematosus (SLE). We present a case of ischemic colitis due to superior mesenteric artery involvement in APS. 59-year-old female patient diagnosed with SLE had sudden-onset hematochezia and acute abdomen. Therefore, the patient underwent contrast-enhanced computed tomography angiography (CT angiography). Thrombosis was detected in the superior mesenteric artery. This case was interesting in terms of different vascular involvement and treatment strategy in the gastrointestinal tract due to APS.
- 4 June 2023
- Published by Ahi Evran Medical Journal, Kirsehir Ahi Evran University in Ahi Evran Medical Journal
- Vol. 8 (1) , 126-129
Open AccessSecondary Anti-phospholipid Antibody Syndrome Due to Systemic Lupus Erythematosus: A Case Report with Superior Mesenteric Artery Involvement
Antiphospholipid antibody syndrome (APS); is a disease characterized by anti-phospholipid protein antibody positivity as well as recurrent vascular thrombosis and/or pregnancy loss. When no underlying disease is detected, it is classified as primary type; when there is another underlying rheumatologic disease, it is classified as secondary type. Secondary APS, most commonly develops due to systemic lupus erythematosus (SLE). We present a case of ischemic colitis due to superior mesenteric artery involvement in APS. 59-year-old female patient diagnosed with SLE had sudden-onset hematochezia and acute abdomen. Therefore, the patient underwent contrast-enhanced computed tomography angiography (CT angiography). Thrombosis was detected in the superior mesenteric artery. This case was interesting in terms of different vascular involvement and treatment strategy in the gastrointestinal tract due to APS.